GSK to Acquire RAPT Therapeutics in Cash Merger

RAPT Therapeutics ( (RAPT) ) has shared an announcement.

On January 19, 2026, RAPT Therapeutics entered into a definitive agreement and plan of merger under which a GSK subsidiary will launch a cash tender offer to acquire all outstanding RAPT shares for $58 per share, implying an equity value of about $2.2 billion and making RAPT a wholly owned GSK unit once a subsequent merger closes. The deal, announced publicly on January 20, 2026, will give GSK global rights outside greater China to ozureprubart, a potentially best-in-class, less-frequently dosed anti-IgE antibody aimed at the growing food allergy market, and is set to strengthen GSK’s Respiratory, Immunology & Inflammation pipeline while offering RAPT shareholders a substantial cash exit, contingent on customary antitrust clearance and a majority tender of shares.

The most recent analyst rating on (RAPT) stock is a Buy with a $39.00 price target. To see the full list of analyst forecasts on RAPT Therapeutics stock, see the RAPT Stock Forecast page.

Spark’s Take on RAPT Stock

According to Spark, TipRanks’ AI Analyst, RAPT is a Neutral.

The score is most constrained by weak financial performance (no revenue and heavy, recently worsening cash burn), partially offset by a strong technical uptrend and neutral-to-moderate valuation signals given losses and no dividend.

To see Spark’s full report on RAPT stock, click here.

More about RAPT Therapeutics

RAPT Therapeutics is a California-based, clinical-stage, immunology-focused biopharmaceutical company developing novel therapies for patients with inflammatory and immunologic diseases, including ozureprubart, a long-acting anti-IgE monoclonal antibody now in phase IIb development for prophylactic protection against food allergens.

Average Trading Volume: 455,395

Technical Sentiment Signal: Buy

Current Market Cap: $972.7M

For detailed information about RAPT stock, go to TipRanks’ Stock Analysis page.